AFP and hepatocellular carcinoma: Other potential prognostic factors, such as age, gender, serum AFP levels, Child-Pugh class B, extrahepatic metastases, portal vein thrombosis, HCC treatment before sorafenib therapy, and stopping sorafenib therapy due to side effect intolerance, were not found to be significantly associated with patient mortality in this study.